Davies et al_SEESAW EASD 2020 abstract_main outcomes.pdf (339.87 kB)
Download file

The SGLT2 inhibitor empagliflozin does not stimulate compensatory appetite responses in patients with excess adiposity and type 2 diabetes

Download (339.87 kB)
conference contribution
posted on 13.10.2020, 09:43 by Melanie J Davies, Emma L Baldry, Danielle H Bodicoat, S Chatterjee, Charlotte L Edwardson, Laura J Gray, Kamlesh Khunti, Jack A Sargeant, David J Stensel, David R Webb, John P H Wilding, Scott A Willis, Tom Yates, James A King
Conference abstract

Funding

Boehringer Ingelheim and supported in-kind by the NIHR Leicester BRC

History

Citation

Diabetologia 63, 1–485 (2020). https://doi.org/10.1007/s00125-020-05221-5

Author affiliation

Diabetes Research Centre, College of Life Sciences

Source

56th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD)

Version

AM (Accepted Manuscript)

Published in

DIABETOLOGIA

Volume

63

Issue

SUPPL 1

Pagination

S116 - S116

Publisher

Springer

issn

0012-186X

eissn

1432-0428

Copyright date

2020

Available date

25/08/2021

Spatial coverage

ELECTR NETWORK

Temporal coverage: start date

21/09/2020

Temporal coverage: end date

25/09/2020

Language

en